HK1053428A1 - Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect - Google Patents
Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defectInfo
- Publication number
- HK1053428A1 HK1053428A1 HK03105815A HK03105815A HK1053428A1 HK 1053428 A1 HK1053428 A1 HK 1053428A1 HK 03105815 A HK03105815 A HK 03105815A HK 03105815 A HK03105815 A HK 03105815A HK 1053428 A1 HK1053428 A1 HK 1053428A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- combination
- ghrp
- egf
- organs
- useful
- Prior art date
Links
- 230000000451 tissue damage Effects 0.000 title abstract 2
- 231100000827 tissue damage Toxicity 0.000 title abstract 2
- 230000007547 defect Effects 0.000 title 1
- 230000002262 irrigation Effects 0.000 title 1
- 238000003973 irrigation Methods 0.000 title 1
- 208000034486 Multi-organ failure Diseases 0.000 abstract 2
- 208000010718 Multiple Organ Failure Diseases 0.000 abstract 2
- 230000017531 blood circulation Effects 0.000 abstract 2
- 230000006364 cellular survival Effects 0.000 abstract 2
- 230000000302 ischemic effect Effects 0.000 abstract 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 abstract 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 abstract 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000004221 Multiple Trauma Diseases 0.000 abstract 1
- 206010051606 Necrotising colitis Diseases 0.000 abstract 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 239000003324 growth hormone secretagogue Substances 0.000 abstract 1
- 230000001146 hypoxic effect Effects 0.000 abstract 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 abstract 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000017423 tissue regeneration Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20010005A CU23157A1 (es) | 2001-01-03 | 2001-01-03 | COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL |
PCT/CU2001/000013 WO2002053167A2 (es) | 2001-01-03 | 2001-12-17 | Combinacion farmaceutica para el tratamiento del dano tisular debido a falta de irrigacion sanguinea arterial |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1053428A1 true HK1053428A1 (en) | 2003-10-24 |
Family
ID=40091523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03105815A HK1053428A1 (en) | 2001-01-03 | 2003-08-14 | Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect |
Country Status (21)
Country | Link |
---|---|
US (1) | US7361638B2 (ja) |
EP (1) | EP1354597B1 (ja) |
JP (2) | JP4181875B2 (ja) |
KR (1) | KR100839857B1 (ja) |
CN (1) | CN1247256C (ja) |
AR (1) | AR032217A1 (ja) |
AT (1) | ATE302017T1 (ja) |
AU (1) | AU2002216897A1 (ja) |
BR (1) | BRPI0108882B8 (ja) |
CA (2) | CA2398983C (ja) |
CU (1) | CU23157A1 (ja) |
DE (1) | DE60112807T2 (ja) |
DK (1) | DK1354597T3 (ja) |
EA (2) | EA006036B1 (ja) |
ES (1) | ES2248229T3 (ja) |
HK (1) | HK1053428A1 (ja) |
MX (1) | MXPA02008667A (ja) |
MY (1) | MY129079A (ja) |
SI (1) | SI1354597T1 (ja) |
WO (1) | WO2002053167A2 (ja) |
ZA (1) | ZA200206954B (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1688696A (zh) * | 2002-09-18 | 2005-10-26 | 蒙特利尔大学医疗中心 | Ghrh类似物 |
US20070123470A1 (en) * | 2003-10-24 | 2007-05-31 | Wladimir Hogenhuis | Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue |
EP1529533A1 (en) * | 2003-11-06 | 2005-05-11 | Sahltech I Göteborg AB | Use of GH secretagogues in hypoxic-ischemic brain injury |
US20070254837A1 (en) * | 2003-12-16 | 2007-11-01 | University Technologies International Inc. | Treatment for Necrotizing Enterocolitis |
CU23529A1 (es) * | 2005-03-02 | 2010-06-17 | Ct Ingenieria Genetica Biotech | Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune |
CU23389B6 (es) * | 2005-12-29 | 2009-07-16 | Ct Ingenieria Genetica Biotech | Combinación farmacéutica citoprotectora, útil en la prevención y tratamiento del síndrome de respuesta inflamatoria sistémica |
CU23592A1 (es) * | 2006-02-28 | 2010-11-11 | Ct Ingenieria Genetica Biotech | Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6 |
CU23526B6 (es) | 2006-10-03 | 2010-05-19 | Ct Ingenieria Genetica Biotech | Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética |
CA2677045C (en) | 2007-01-31 | 2016-10-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
CA2682174C (en) | 2007-03-28 | 2021-04-06 | President And Fellows Of Harvard College | Stitched polypeptides |
US8093213B2 (en) * | 2007-04-30 | 2012-01-10 | Nationwide Children's Hospital, Inc. | Heparin binding epidermal growth factor (HB-EGF) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation |
JP5797112B2 (ja) | 2008-07-17 | 2015-10-21 | アコーダ セラピューティクス インコーポレイテッド | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
WO2012021876A2 (en) | 2010-08-13 | 2012-02-16 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
CN108929375A (zh) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | 拟肽大环化合物 |
ES2817877T3 (es) | 2012-02-15 | 2021-04-08 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos |
WO2013123267A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
JP6526563B2 (ja) | 2012-11-01 | 2019-06-05 | エイルロン セラピューティクス,インコーポレイテッド | 二置換アミノ酸ならびにその調製および使用の方法 |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
SG10201902594QA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
CA2979847A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
KR20170001567A (ko) | 2015-06-26 | 2017-01-04 | 주식회사 파마리서치프로덕트 | 어류의 정액 또는 정소로부터 분리된 dna 단편 혼합물을 포함하는 허혈성 장염의 예방 또는 치료용 조성물 |
US11197944B2 (en) | 2015-11-18 | 2021-12-14 | President And Fellows Of Harvard College | Compositions and methods of mechanically inducing tissue regeneration |
CU24591B1 (es) * | 2018-08-21 | 2022-04-07 | Ct Ingenieria Genetica Biotecnologia | Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento |
MX2021002069A (es) * | 2018-08-21 | 2021-04-28 | Ct Ingenieria Genetica Biotecnologia | Uso del ghrp-6 como cardioprotector y cardiorestaurador tardio. |
CN109908331A (zh) * | 2019-04-30 | 2019-06-21 | 青岛大学附属医院 | 海沙瑞林在制备保护肾脏缺血再灌注损伤药物/药物组合物中的应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057494A (en) | 1988-08-03 | 1991-10-15 | Ethicon, Inc. | Method for preventing tissue damage after an ischemic episode |
US5360790A (en) * | 1990-12-11 | 1994-11-01 | The Regents Of The University Of Michigan | Method and formulations for the therapy of acute renal failure |
KR970032600A (ko) | 1995-12-30 | 1997-07-22 | 배순훈 | 전기압력보온밥솥용 압력센싱장치의 이상 발생인식방법 |
SE9703929D0 (sv) | 1996-11-22 | 1997-10-28 | Pharmacia & Upjohn Ab | Therapeutical use and method |
KR100226985B1 (ko) * | 1997-07-14 | 1999-10-15 | 윤재승 | 신규한 인간성장호르몬방출인자-인간상피세포성장인자 융합유전자, 이의 발현벡터 및 이를 이용한 인간성장호르몬방출인자의 제조방법 |
US6191109B1 (en) * | 1997-10-31 | 2001-02-20 | Children's Hospital, Inc. | Methods of treating intestinal ischemia using heparin-binding epidermal growth factor |
US6124263A (en) * | 1998-11-16 | 2000-09-26 | Asta Medica Ag | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
CA2341649A1 (en) | 1998-09-02 | 2000-03-09 | Merck & Co., Inc. | Enhancement of return to independent living status with a growth hormone secretagogue |
US6194578B1 (en) * | 1998-11-20 | 2001-02-27 | Pfizer Inc. | Dipeptide derivatives |
DE60115227T2 (de) | 2000-05-11 | 2006-08-24 | Bristol-Myers Squibb Co. | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
CA2380423A1 (en) * | 2000-05-17 | 2001-11-22 | Bionebraska, Inc. | Peptide pharmaceutical formulations |
ATE302181T1 (de) * | 2000-06-13 | 2005-09-15 | Zentaris Gmbh | Verbindungen zur stimulation der sekretion von wachstumshormonen |
-
2001
- 2001-01-03 CU CU20010005A patent/CU23157A1/es unknown
- 2001-12-17 AU AU2002216897A patent/AU2002216897A1/en not_active Abandoned
- 2001-12-17 MX MXPA02008667A patent/MXPA02008667A/es active IP Right Grant
- 2001-12-17 EP EP01272599A patent/EP1354597B1/en not_active Expired - Lifetime
- 2001-12-17 SI SI200130436T patent/SI1354597T1/sl unknown
- 2001-12-17 AT AT01272599T patent/ATE302017T1/de active
- 2001-12-17 WO PCT/CU2001/000013 patent/WO2002053167A2/es active IP Right Grant
- 2001-12-17 EA EA200200850A patent/EA006036B1/ru not_active IP Right Cessation
- 2001-12-17 CA CA2398983A patent/CA2398983C/en not_active Expired - Lifetime
- 2001-12-17 EA EA200500646A patent/EA007466B1/ru not_active IP Right Cessation
- 2001-12-17 BR BRPI0108882A patent/BRPI0108882B8/pt not_active IP Right Cessation
- 2001-12-17 DE DE60112807T patent/DE60112807T2/de not_active Expired - Lifetime
- 2001-12-17 US US10/220,750 patent/US7361638B2/en not_active Expired - Lifetime
- 2001-12-17 CA CA 2789161 patent/CA2789161C/en not_active Expired - Lifetime
- 2001-12-17 DK DK01272599T patent/DK1354597T3/da active
- 2001-12-17 JP JP2002554116A patent/JP4181875B2/ja not_active Expired - Fee Related
- 2001-12-17 KR KR1020027011276A patent/KR100839857B1/ko active IP Right Grant
- 2001-12-17 CN CNB018059783A patent/CN1247256C/zh not_active Expired - Lifetime
- 2001-12-17 ES ES01272599T patent/ES2248229T3/es not_active Expired - Lifetime
- 2001-12-19 MY MYPI20015758A patent/MY129079A/en unknown
- 2001-12-28 AR ARP010106097A patent/AR032217A1/es unknown
-
2002
- 2002-08-29 ZA ZA200206954A patent/ZA200206954B/en unknown
-
2003
- 2003-08-14 HK HK03105815A patent/HK1053428A1/xx unknown
-
2008
- 2008-05-30 JP JP2008141792A patent/JP4958844B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1053428A1 (en) | Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect | |
Silverstein | Smoking and wound healing | |
HASANI | Overview of diabetic foot; novel treatments in diabetic foot ulcer | |
JP2003517887A (ja) | 傷、熱傷、および、免疫系障害の治療装置および治療方法 | |
Niezgoda et al. | The effect of hyperbaric oxygen therapy on a burn wound model in human volunteers | |
US7833522B2 (en) | Apparatus and method to treat a wound area | |
IS7912A (is) | Notkun dókósahexensýru sem virks efnis til að meðhöndla fitukyrking | |
Hollander et al. | Hyperbaric oxygen therapy for wound dehiscence after intraoral bone grafting in the nonirradiated patient: a case series | |
Tenenhaus et al. | Burn surgery | |
NO20071238L (no) | Fremgangsmater for leging av skader ved human IL-18 administrering | |
JP5796728B1 (ja) | 創傷治癒を促進し生体諸臓器の被覆(コーチング)及び庇護を目的とした生体皮膜剤。 | |
Ismail | Hyperbaric oxygen therapy as a complementary or alternative therapy for chronic oral and gastrointestinal disorders: A narrative review | |
NO841275L (no) | Fremgangsmaate for fremstilling av et preparat mot buergers sykdom. | |
RU2582228C1 (ru) | Способ профилактики и лечения послеоперационного воспаления полости рта | |
Lee et al. | Hemostatic materials in non-variceal upper gastrointestinal hemorrhage | |
Menendi et al. | The effects of carbogen and hyperbaric oxygen treatment on fracture healing in rats | |
US6387360B1 (en) | Anti-jaundice composition for corpses and method | |
Koscielniak‐Nielsen et al. | Intra‐arterial regional anaesthesia for hand surgery: a dose‐finding study | |
Lodhi et al. | Total thyroidectomy in Benign multinodular goitre | |
Strauss et al. | Cigarette smoking and transcutaneous oxygen tensions: a case report | |
Sapienza et al. | A multidisciplinary approach to a complex case of lower limb trauma | |
ES2164614A1 (es) | Mezcla de helio y oxigeno con aplicacion terapeutica. | |
TH66198B (th) | องค์ประกอบทางเภสัชศาสตร์ในการรักษาความเสียหายของเนื้อเยื่อ เนื่องจากการล้มเหลวของการไหลเวียนโลหิตของเส้นเลือดแดงใหญ่ | |
RU2190400C2 (ru) | Способ лечения респираторного дистресс-синдрома | |
Vico et al. | Achilles tendon cover using a free lateral arm fascial flap |